- Shares of Prosensa (RNA -1.9%) are weaker on the session.
- Chatter indicates the move might be attributable to a new paper discussing the pharmacokinetics and safety of drisapersen in non-ambulant DMD patients. (full article)
- Shares of Sarepta Therapeutics (SRPT) spiked early before quickly retracing gains.
Prosensa slips, drisapersen paper in focus
Sep 16 2013, 11:42 ET